Active, not recruitingPhase 2NCT03347838

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Studying Holt-Oram syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Colorado, Denver
Principal Investigator
Robert Keith, MD
University of Colorado, Denver
Intervention
Nivolumab(drug)
Enrollment
19 target
Eligibility
18-80 years · All sexes
Timeline
20192026

Study locations (2)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03347838 on ClinicalTrials.gov

Other trials for Holt-Oram syndrome

Additional recruiting or active studies for the same condition.

See all trials for Holt-Oram syndrome

← Back to all trials